Basis: FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/S ratio is N/A as of 2026-10-06T20:33:27.019Z.
Calculation as of: 2026-10-06T20:33:27.019Z.
Quote observation: 2026-10-06T20:00:01.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 0fde8dae4c5ae63ee7b35c7e6e46bba2fdf5d6d5db310b32cf0eb41a7e17e840
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PS RATIO
N/A
Market Cap
$225.24M
PS Ratio
1185.48
TTM Avg
678.70
3Y Avg
678.70
5Y Avg
678.70
| NAME | MARKET CAP | PS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Vogenx Inc. (VOGX) | $227.91M | N/A | N/A | N/A | N/A |
| Biodesix, Inc. (BDSX)vs › | $227.60M | 2.21 | 1.47 | 2.05 | 2.05 |
| Nautilus Biotechnolgy, Inc. (NAUT)vs › | $225.24M | 1185.48 | 678.70 | 678.70 | 678.70 |
| MacroGenics, Inc. (MGNX)vs › | $231.37M | 1.38 | 1.23 | 3.39 | 3.84 |
| Greenwich LifeSciences, Inc. (GLSI)vs › | $231.77M | N/A | N/A | N/A | N/A |
| InflaRx N.V. (IFRX)vs › | $232.72M | N/A | 1866.99 | 1234.73 | 1234.73 |
| Profound Medical Corp. (PROF)vs › | $220.93M | 11.62 | 13.79 | 19.84 | 21.38 |
| Utah Medical Products, Inc. (UTMD)vs › | $235.08M | 6.51 | 5.47 | 5.19 | 5.79 |
| Akebia Therapeutics, Inc. (AKBA)vs › | $235.66M | 1.08 | 1.71 | 2.09 | 1.59 |
| SIGA Technologies, Inc. (SIGA)vs › | $235.97M | 4.40 | 3.23 | 4.18 | 4.64 |
The four-quarter calculation detail is unavailable for this stored observation.
The current P/S calculation cannot be reconciled from the stored quote and revenue inputs.
These references are supplied through FMP. Full filing context identifiers and dimensional metadata are unavailable in the normalized feed.
P/S Ratio
N/A
Market Cap / Trailing Twelve-Month Revenue
PS Ratio = Market Cap / Revenue (TTM)
The price-to-sales ratio compares market capitalization to trailing revenue. It is useful for valuing companies with little or no earnings.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
